{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:42Z","timestamp":1793766462689,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102653","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:44Z","timestamp":1787068124000},"page":"102653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9030-022X","authenticated-orcid":false,"given":"U\u011fur","family":"\u00d6zberk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahriye Tu\u011fba","family":"K\u00f6\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perihan","family":"Perkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6znur","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-7111","authenticated-orcid":false,"given":"Berkay","family":"Ye\u015filyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Akif","family":"Parlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Delen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102653_bib0001","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2026.102653_bib0002","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/jjco\/hyz013","article-title":"Overview of current and future systemic therapy for metastatic renal cell carcinoma","volume":"49","author":"Osawa","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102653_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clgc.2026.102653_bib0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102653_bib0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102653_bib0006","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102653_bib0007","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102653_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102653_bib0009","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.euf.2021.11.006","article-title":"Real-world data on the use of nivolumab monotherapy in the treatment of advanced renal cell carcinoma after prior therapy: interim results from the noninterventional NORA study","volume":"8","author":"Grimm","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102653_bib0010","first-page":"14","article-title":"Chronotherapy: circadian rhythms and their influence in cancer therapy","author":"Amiama-Roig","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102653_bib0011","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/07487304211044301","article-title":"Circadian rhythms, disease and chronotherapy","volume":"36","author":"Lee","year":"2021","journal-title":"J Biol Rhythms"},{"key":"10.1016\/j.clgc.2026.102653_bib0012","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1470-2045(00)00326-0","article-title":"Circadian chronotherapy for human cancers","volume":"2","author":"Levi","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102653_bib0013","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102653_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1352","article-title":"967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer","volume":"32","author":"Vilalta","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102653_bib0015","series-title":"Impact of Time-of-day Administration of Immunotherapy on Overall Survival among Patients with Metastatic Renal Cell Carcinoma","author":"Arroyave Ramirez","year":"2024"},{"key":"10.1016\/j.clgc.2026.102653_bib0016","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.clgc.2023.06.004","article-title":"Association between time-of-day of Immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma","volume":"21","author":"Dizman","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102653_bib0017","series-title":"A Single-center Study","article-title":"Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma?","author":"Fernandez-Ma\u00f1as","year":"2023"},{"key":"10.1016\/j.clgc.2026.102653_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008011","article-title":"Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2026.102653_bib0019","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","article-title":"Dendritic cells direct circadian anti-tumour immune responses","volume":"614","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2026.102653_bib0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00002371-199211000-00001","article-title":"Improving responses in hepatomas with circadian-patterned hepatic artery infusions of recombinant interleukin-2","volume":"12","author":"Kemeny","year":"1991","journal-title":"J Immunother"},{"key":"10.1016\/j.clgc.2026.102653_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162068","article-title":"Immunotherapy around the clock: impact of infusion timing on stage IV melanoma outcomes","volume":"12","author":"Goncalves","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.clgc.2026.102653_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2023.01.007","article-title":"Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"182","author":"Rousseau","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102653_bib0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12967-022-03601-6","article-title":"The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study","volume":"20","author":"Rebuzzi","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.clgc.2026.102653_bib0024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of Nivolumab plus Ipilimumab versus Sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:17:10Z","timestamp":1793765830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001539"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102653","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102653"}}